Pharmacological inhibition of MIF using the MIF irreversible inhibitor, 4-iodo-6-phenylpyrimidine (4-IPP) has shown a decrease in tumor aggressiveness in head and neck squamous cell carcinomas [17] and lung adenocarcinomas [23]. Here, MIF is linked to head and neck squamous cell carcinoma.